Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | 10% owner | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 750,000 |
Reported balance
After 2018-06-29 transaction · row 1
1 source rowRow 1 · 2018-06-29 · Purchase · Acquired 250,000 · Balance 750,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2018 Filed Jul 3, 2018 16:16 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseCommon Stock | 250,000 | $3.60 | $900,000.00 |
DisclosureSEC source: 0001144204-18-037230 · tv498009_4.xml · nonDerivative · entry 1 Du Xiaoyu · CIK 0001743458 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.